Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: Identification of metabolites and routes of elimination

References

• Bibby M. C., Double J. A., Loadman P. M., Duke C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. Journal of the National Cancer Institute 1989; 81: 216–220
   PubMed Web of Science ®Google Scholar
• Bibby M. C., Double J. A., Phillips R. M., Loadman P. M. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). British Journal of Cancer 1987; 55: 159–164
   PubMed Web of Science ®Google Scholar
• Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metabolism Reviews 1981; 12: 221–237
   PubMed Web of Science ®Google Scholar
• Chabot G. G., Bissery M.-C., Corbett T. C., Rutkowski K., Baker L. H. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemotherapy and Pharmacology 1989; 24: 15–22
   PubMed Web of Science ®Google Scholar
• Chabot G. G., Gouyette A. Reactivity of flavone acetic acid and its acyl glucuronide. Biochemical Pharmacology 1991; 42: 1145–1148
   PubMed Web of Science ®Google Scholar
• Cummings J., Double J. A., Bibby M. C., Farmer P., Evans S., Kerr D. J., Kaye S. B., Smyth J. F. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Research 1989; 49: 3587–3593
   PubMed Web of Science ®Google Scholar
• Damia G., Garofalo A., Rossi C., Giavazzi R., D'Incalci M. Flavone acetic acid pharmacokinetics in nude mice. Anticancer Research 1990; 10: 437–439
   Google Scholar
• Damia G., Zanette M. L., Rossi C., Mandelli R., Ferrari A., D'Icalci M. Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemotherapy and Pharmacology 1988; 22: 47–50
   Google Scholar
• Emudianughe T. S., Caldwell J., Sinclair K. A., Smith R. L. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metabolism and Disposition 1983; 11: 97–102
   PubMedGoogle Scholar
• Evelhoch J. L., Bissery M.-C., Chabot G. G., Simpson N. E., McCoy C. L., Heilbrun L. K., Corbett T. H. Flavone acetic acid (NSC 347512)- induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Research 1988; 48: 4749–4755
   PubMed Web of Science ®Google Scholar
• Faed E. M. Properties of acyl glucuronides: implications for studies of the pharmacokiinetics and metabolism of acidic drugs. Drug Metabolism Reviews 1984; 15: 1213–1249
   PubMed Web of Science ®Google Scholar
• Finlay G. J., Smith G. P., Fray L. M., Baguley B. C. Effect of flavone acetic acid (NSC 347512) on Lewis lung carcinoma, evidence for an indirect effect. Journal of the National Cancer Institute 1988; 80: 241–245
   PubMed Web of Science ®Google Scholar
• Fulco A. J. Metabolic alterations of fatty acids. Annual Review of Biochemistry 1974; 43: 215–241
   PubMedGoogle Scholar
• Futami H., Eader L. A., Back T. T., Gruys E., Young H. A., Wiltrout R. H., Baguley B. C. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. Journal of Immunotherapy 1992; 12: 247–255
   PubMed Web of Science ®Google Scholar
• Griffiths L. A. Metabolism of xanthenone in the rat. Xenobiotica 1974; 4: 375–382
   Web of Science ®Google Scholar
• Havlin K. A., Kuhn J. G., Craig J. B., Boldt D. H., Weiss G. R., Koeller J., Harman G., Schwartz R., Clark G. N., von Hoff D. D. Phase I clinical and pharmacokinetic trial of flavone acetic acid. Journal of the National Cancer Institute 1991; 83: 124–128
   PubMed Web of Science ®Google Scholar
• Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochemical Pharmacology 1983; 32: 1141–1148
   PubMed Web of Science ®Google Scholar
• Kerr D. J., Kaye S. B. Flavone acetic acid—preclinical and clinical activity. European Journal of Cancer and Clinical Oncology 1989; 25: 1271–1272
   PubMedGoogle Scholar
• Kerr D., Kaye S. B., Cassidy J., Bradley C., Rankin E., Adams L., Setanoians A., Young T., Forrest G., Soukop M., Clavel M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Research 1987; 47: 6776–6781
   PubMed Web of Science ®Google Scholar
• Kestell P., McKeage M. J., Baguley B. C. Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography. Journal of Chromatography 1991; 564: 315–321
   Google Scholar
• Klassen C. D., Eaton D. L., Cagen S. Z. Hepatobiliary disposition of xenobiotics. Progress in Drug Metabolism, J. W. Bridges, L. F. Chasseaud. Taylor & Francis, London 1981; 1–75
   Google Scholar
• Mace K. F., Hornung R. L., Wiltrout R. H., Young H. A. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Research 1990; 50: 1742–1747
   PubMed Web of Science ®Google Scholar
• McKeage M. J., Kestell P., Denny W. A., Baguley B. C. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemotherapy and Pharmacology 1991; 28: 409–413
   PubMed Web of Science ®Google Scholar
• Meffin P. J., Zilm D. M., Veenendaal J. R. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 732–738
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Shoemaker D., Zaharko S., Grieshaber C., Plowman J., Corbett T., Valeriote F., King S. A., Cradock J., Hoth F., Leyland-Jones B. Flavone acetic acid (LM 975, NSC 347512), a novel antitumor agent. Cancer Chemotherapy and Pharmacology 1987; 19: 6–10
   Google Scholar
• Plowman J., Naryanan V. L., Dykes D., Szarvasi E., Briet P., Yoder O. C., Paull K. D. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treatment Reports 1986; 70: 631–638
   PubMedGoogle Scholar
• Rewcastle G. W., Atwell G. J., Baguley B. C., Calveley S. B., Denny W. A. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. Journal of Medicinal Chemistry 1989; 32: 793–799
   PubMed Web of Science ®Google Scholar
• Rewcastle G. W., Atwell G. J., Zhuang L., Baguley B. C., Denny W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. Journal of Medicinal Chemistry 1991; 34: 217–222
   PubMed Web of Science ®Google Scholar
• Roberts J. C. Naturally occurring xanthones. Chemical Reviews 1961; 61: 591–605
   Web of Science ®Google Scholar
• Smith G. P., Calveley S. B., Smith M. J., Baguley B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. European Journal of Cancer and Clinical Oncology 1987; 23: 1209–1212
   PubMedGoogle Scholar
• Stokke O., Try K., Eldjara L. α-Oxidation as an alternative pathway for the degradation of branched-chain fatty acids in man, and its failure in patients with Refsum's disease. Biochimica et Biophysica Acta 1967; 144: 271–284
   PubMed Web of Science ®Google Scholar
• Stumpf P. K. Metabolism of fatty acids. Annual Review of Biochemistry 1969; 38: 159–212
   PubMed Web of Science ®Google Scholar
• Thierfelder K., Daiber K. Behaviour of aliphatic-aromatic ketones in the animal body. Hoppe Seyler's Zeitschrift für Physiologie und Chemnie 1923; 130: 380–396
   Google Scholar
• Thierfelder K., Klenk E. The behaviour of acetophenone and benzene in the animal body. Hoppe Seyler's Zeitschrift für Physiologie und Chemie 1924; 141: 29–32
   Google Scholar
• Thomassin J., Battaglia C., Allievi C., Casttelli M. G., Strolin Benedetti M. In vivo glucuronidation in rat and humans of 5,6-dihydro-7-(1H-imidazol-l-yl)-naphthalene-2-carboxylic acid, a selective inhibitor of thromboxane synthase. Drug Metabolism and Disposition 1993; 21: 151–155
   Google Scholar
• Thomsen L. L., Ching L. M., Baguley B. C. Evidence for the production of nitric acid by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Research 1990; 50: 6966–6970
   PubMed Web of Science ®Google Scholar
• Thomsen L. L., Ching L. M., Zhuang L., Gavin J. B., Baguley B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Research 1991; 51: 77–81
   PubMed Web of Science ®Google Scholar
• Weiss R. B., Green R. F., Knight R. D., Collins J. M., Pelosi J. J., Sulkes A., Curt G. A. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512. Cancer Research 1988; 48: 5878–5882
   PubMed Web of Science ®Google Scholar
• Zaharko D. S., Griehaber C. K., Plowman J., Cradock J. C. Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treatment Reports 1986; 70: 1415–1421
   PubMedGoogle Scholar
• Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). Journal of the National Cancer Institute 1989; 81: 1005–1013
   PubMed Web of Science ®Google Scholar